Form 4: Cytek Biosciences CFO Boosts Stake with Significant Stock Purchase

Cytek Biosciences' Chief Financial Officer, William D. McCombe, has acquired 35,000 shares of common stock at a weighted average price of $2.78 per share, increasing his beneficial ownership to 55,746 shares.

Summary

• William D. McCombe, Chief Financial Officer of Cytek Biosciences, Inc. (CTKB), reported a transaction on June 2, 2025.
• The transaction involved the acquisition of 35,000 shares of Cytek Biosciences common stock.
• The shares were purchased at a weighted average price of $2.78 per share, with individual transaction prices ranging from $2.76 to $2.81.
• Following this acquisition, Mr. McCombe's direct beneficial ownership of Cytek Biosciences common stock increased to 55,746 shares.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to a significant insider purchase by a key executive, indicating strong internal confidence in the company's prospects.

Positives

• The Chief Financial Officer's purchase of 35,000 shares indicates strong confidence in the company's future prospects and valuation.
• This acquisition significantly increases the CFO's direct beneficial ownership, further aligning management's interests with those of shareholders.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders may interpret the CFO's stock purchase as a strong vote of confidence in Cytek Biosciences' future, potentially leading to increased investor interest and positive sentiment.

Key Dates

Recommendation

Keywords

Cytek Biosciences, CTKB, Form 4, insider trading, stock purchase, CFO, beneficial ownership, equity acquisition